{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:45:36Z","timestamp":1761821136286},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2002,4]]},"DOI":"10.1016\/s0197-0186(01)00101-2","type":"journal-article","created":{"date-parts":[[2002,10,14]],"date-time":"2002-10-14T19:11:54Z","timestamp":1034622714000},"page":"435-440","source":"Crossref","is-referenced-by-count":35,"title":["The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine"],"prefix":"10.1016","volume":"40","author":[{"given":"Ant\u00f3nio","family":"Parada","sequence":"first","affiliation":[]},{"given":"Patr\u0131\u0301cio","family":"Soares-da-Silva","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0197-0186(01)00101-2_BIB1","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0006-2952(01)00584-6","article-title":"Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels","volume":"61","author":"Ambrosio","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/S0197-0186(01)00101-2_BIB2","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/jm980627g","article-title":"Anticonvulsant and sodium channel-blocking properties of novel 10,11- dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives","volume":"42","author":"Benes","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/S0197-0186(01)00101-2_BIB3","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1528-1157.2001.43600.x","article-title":"Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine","volume":"42","author":"Bonif\u00e1cio","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/S0197-0186(01)00101-2_BIB4","first-page":"441","article-title":"Molecular properties of brain sodium channels: an important target for anticonvulsant drugs","volume":"79","author":"Catterall","year":"1999","journal-title":"Adv. Neurol."},{"key":"10.1016\/S0197-0186(01)00101-2_BIB5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1528-1157.1987.tb03661.x","article-title":"Common anticonvulsants inhibit Ca2+ uptake and amino acid neurotransmitter release in vitro","volume":"28","author":"Crowder","year":"1987","journal-title":"Epilepsia"},{"key":"10.1016\/S0197-0186(01)00101-2_BIB6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0920-1211(89)90070-3","article-title":"A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy","volume":"3","author":"Dam","year":"1989","journal-title":"Epilepsy Res."},{"key":"10.1016\/S0197-0186(01)00101-2_BIB7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0165-0270(96)00095-7","article-title":"Modifications of the brandel superfusion 600 system and other revisions in superfusion technique improve the measurement of endogenous dopamine release in vitro","volume":"68","author":"Delledonne","year":"1996","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/S0197-0186(01)00101-2_BIB8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/0006-8993(95)00327-M","article-title":"Rat brain neurotransmitter turnover rates altered during withdrawal from chronic cocaine administration","volume":"682","author":"Dworkin","year":"1995","journal-title":"Brain Res."},{"issue":"Suppl. 3","key":"10.1016\/S0197-0186(01)00101-2_BIB9","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1111\/j.1528-1157.1987.tb05772.x","article-title":"Pharmacology of antiepileptic drugs","volume":"28","author":"Ferrendelli","year":"1987","journal-title":"Epilepsia"},{"key":"10.1016\/S0197-0186(01)00101-2_BIB10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0920-1211(01)00231-5","article-title":"Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(\u2212)-10,11-dihydro-10-hydroxy carbamazepine","volume":"44","author":"Hainzl","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/S0197-0186(01)00101-2_BIB11","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1528-1157.1986.tb03573.x","article-title":"Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action","volume":"27","author":"Leach","year":"1986","journal-title":"Epilepsia"},{"key":"10.1016\/S0197-0186(01)00101-2_BIB12","first-page":"107","article-title":"Effects of BIA 2-059 and BIA 2-093 on motor impairment in rats and mice","volume":"12","author":"Learmonth","year":"2000","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/S0197-0186(01)00101-2_BIB13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0197-0186(00)00076-0","article-title":"The reverse transport of DA, what physiological significance","volume":"38","author":"Leviel","year":"2001","journal-title":"Neurochem. Int."},{"key":"10.1016\/S0197-0186(01)00101-2_BIB14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1528-1157.1995.tb05996.x","article-title":"Antiepileptic drug mechanisms of action","volume":"36","author":"Macdonald","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/S0197-0186(01)00101-2_BIB15","doi-asserted-by":"crossref","unstructured":"Mattson, R.H., Cramer, J.A., Collins, J.F., Smith, D.B., Delgado-Escueta, A.V., Browne, T.R., Williamson, P.D., Treiman, D.M., McNamara, J.O., McCutchen, C.B., et al., 1985. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalised tonic-clonic seizures. New Eng. J. Med. 313, 145\u2013151.","DOI":"10.1056\/NEJM198507183130303"},{"key":"10.1016\/S0197-0186(01)00101-2_BIB16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1528-1157.1994.tb05949.x","article-title":"Oxcarbazepine: mechanisms of action","volume":"35","author":"McLean","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/S0197-0186(01)00101-2_BIB17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1528-1157.1986.tb03572.x","article-title":"Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats","volume":"27","author":"Miller","year":"1986","journal-title":"Epilepsia"},{"key":"10.1016\/S0197-0186(01)00101-2_BIB18","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1528-1157.1994.tb05951.x","article-title":"Standard approach to antiepileptic drug treatment in the United States","volume":"35","author":"Pellock","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/S0197-0186(01)00101-2_BIB19","first-page":"223","article-title":"Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds (Review)","volume":"42","author":"Rogawski","year":"1990","journal-title":"Pharmacol. Rev."},{"issue":"Suppl. 5","key":"10.1016\/S0197-0186(01)00101-2_BIB20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1528-1157.1994.tb05967.x","article-title":"Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action (see comments)","volume":"35","author":"Schmutz","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/S0197-0186(01)00101-2_BIB21","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/0028-3908(90)90039-T","article-title":"Overflow of endogenous dopamine and 3,4-dihydroxyphenylacetic acid from tissues of the rat brain, elicited by electrical stimulation, depolarization by potassium and activation of carrier-mediated release","volume":"29","author":"Soares-da-Silva","year":"1990","journal-title":"Neuropharmacology"},{"key":"10.1016\/S0197-0186(01)00101-2_BIB22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0197-0186(00)00124-8","article-title":"Excessive release of [3H] noradrenaline by veratridine and ischemia in spinal cord","volume":"39","author":"Sumiya","year":"2001","journal-title":"Neurochem. Int."},{"key":"10.1016\/S0197-0186(01)00101-2_BIB23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1054-3589(08)60069-1","article-title":"Sodium channels and therapy of central nervous system diseases","volume":"39","author":"Taylor","year":"1997","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/S0197-0186(01)00101-2_BIB24","first-page":"439","article-title":"Effects of BIA 2-059 and BIA 2-093 on learning and memory in rats","volume":"12","author":"Vieira-Coelho","year":"2000","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/S0197-0186(01)00101-2_BIB25","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1212\/WNL.45.10.1907","article-title":"Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters","volume":"45","author":"Waldmeier","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/S0197-0186(01)00101-2_BIB26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/BF00178716","article-title":"Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum","volume":"354","author":"Waldmeier","year":"1996","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/S0197-0186(01)00101-2_BIB27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0014-2999(94)90787-0","article-title":"Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalised seizures","volume":"271","author":"Wamil","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/S0197-0186(01)00101-2_BIB28","first-page":"627","article-title":"Inhibition of binding of [3H] batrachotoxinin A 20-alpha-benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine","volume":"22","author":"Willow","year":"1982","journal-title":"Mol. Pharmacol."}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018601001012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018601001012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,4]],"date-time":"2019-05-04T03:25:30Z","timestamp":1556940330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018601001012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["S0197018601001012"],"URL":"https:\/\/doi.org\/10.1016\/s0197-0186(01)00101-2","relation":{},"ISSN":["0197-0186"],"issn-type":[{"value":"0197-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2002,4]]}}}